IFRX Stock Analysis: Buy, Sell, or Hold?
IFRX - InflaRx N.V. Common Stock
$0.97
0.09 (10.42%)
▲
5d:
+4.62%
30d:
-3.56%
90d:
-26.21%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Mar 19, 2026
Get Alerted When IFRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IFRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IFRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IFRX is currently trading at $0.97, which is considered oversold relative to its 30-day fair value range of $0.98 to $1.12.
Technical Outlook: Technically, IFRX is in a strong downtrend. Immediate support is located at $0.87, while resistance sits at $1.07. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: IFRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.50 (+978.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IFRX is in a strong downtrend. Immediate support is located at $0.87, while resistance sits at $1.07. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: IFRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.50 (+978.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.98 -
$1.12
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.4%)
- BULLISH: Trading 978.4% below Wall St target ($10.50)
Fair Price Analysis
30-Day Fair Range
$0.98 -
$1.12
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.87
Resistance Level
$1.07
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.42
Wall Street Target
$10.50
(+978.4%)
Revenue Growth (YoY)
-80.8%
Last updated: February 03, 2026 6:39 AM ET
Data refreshes hourly during market hours. Next update: 7:39 AM
Data refreshes hourly during market hours. Next update: 7:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IFRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 56 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 58 HOLD |
